期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Recent Advances in Fibrinogen Research in Colorectal Cancer 被引量:1
1
作者 Wenjing Jiang Di Wang junyan yu 《Journal of Biosciences and Medicines》 2023年第4期28-38,共11页
Colorectal Cancer (CRC) is a common malignant tumour of the gastrointestinal tract in China, with increasing morbidity and mortality rates year by year. Most patients are in the middle and late stage when diagnosed, a... Colorectal Cancer (CRC) is a common malignant tumour of the gastrointestinal tract in China, with increasing morbidity and mortality rates year by year. Most patients are in the middle and late stage when diagnosed, and its high mortality and poor prognosis have seriously threatened the health and life. Fibrinogen (FIB) is mainly used as a coagulation factor in the body to participate in the process of coagulation and haemostasis, and is the main protein in the coagulation process. In recent years, studies at home and abroad have shown that FIB levels correlate with the diagnosis, outcome prediction and prognosis of CRC, and some of the findings are still controversial. This article aims to review the related research and new progress of the relationship between FIB and CRC in recent years. 展开更多
关键词 FIBRINOGEN Colorectal Cancer Coagulation Function
下载PDF
Efficacy,safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer:an open-label,multicenter,phase Ib trial
2
作者 Jing Zuo Wei Duan +21 位作者 Mingxuan Zhao Zhendong Chen Jie Lin Huaqiu Shi Ou Jiang Youzhong Zhang Meiyu Fang LiWang Wei Wang Yong Huang junyan yu Xiaoxue Zhang Weiqing Pu Deshun Hao Fenglin She Xiugao Yang Ying Chen Qizhi Tang Xiao Zhang Miao Niu Yan’e Song Lingying Wu 《Cancer Communications》 SCIE 2024年第9期1042-1046,共5页
Cervical cancer(CC)is one of the most common gynecological cancers,ranking fourth in incidence and mortality rates among women worldwide and second in China[1].Approximately 15%-61%of patients with CC develop recurren... Cervical cancer(CC)is one of the most common gynecological cancers,ranking fourth in incidence and mortality rates among women worldwide and second in China[1].Approximately 15%-61%of patients with CC develop recurrent or metastatic(r/m)disease in the first two years after initial therapy completion,with a 5-year survival rate of 17%[2].Platinum-based chemotherapy is the first-line treatment for r/mCC. 展开更多
关键词 patients metastatic cancer
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部